Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]
In development [GID-TA10761] Expected publication date: TBC
Search results
509 results
-
-
Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
In development [GID-TA10531] Expected publication date: 15 December 2021
-
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
In development [GID-TA10577] Expected publication date: 21 April 2021
-
Ofatumumab for treating relapsing multiple sclerosis [ID1677]
In development [GID-TA10557] Expected publication date: TBC
-
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]
In development [GID-TA10630] Expected publication date: TBC
-
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]
In development [GID-TA10523] Expected publication date: TBC
-
Mental wellbeing at work
In development [GID-NG10140] Expected publication date: 15 December 2021
-
Reducing sexually transmitted infections
In development [GID-NG10142] Expected publication date: 09 February 2022
-
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]
In development [GID-TA10759] Expected publication date: TBC
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: TBC
-
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia [ID2708]
In development [GID-TA10588] Expected publication date: TBC
-
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
In development [GID-TA10539] Expected publication date: 15 December 2021
-
Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]
In development [GID-TA10566] Expected publication date: TBC
-
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]
In development [GID-TA10391] Expected publication date: TBC
-
Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604
In development [GID-TA10518] Expected publication date: TBC
-
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]
In development [GID-TA10352] Expected publication date: 13 October 2021
-
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]
In development [GID-TA10222] Expected publication date: TBC
-
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
In development [GID-TA10656] Expected publication date: 02 March 2022
-
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
In development [GID-TA10464] Expected publication date: TBC
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: 05 May 2021
-
Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]
In development [GID-TA10591] Expected publication date: TBC
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
In development [GID-TA10457] Expected publication date: 19 May 2021
-
Atrial fibrillation - vernakalant [ID454]
In development [GID-TAG428] Expected publication date: TBC
-
Conjunctivitis: antimicrobial prescribing
In development [GID-NG10166] Expected publication date: TBC
-
Idebenone for treating Duchenne muscular dystrophy ID1092
In development [GID-TA10310] Expected publication date: TBC
-
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
-
Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]
In development [GID-TA10649] Expected publication date: 22 September 2021
-
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]
In development [GID-TA10756] Expected publication date: 22 September 2021
-
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610
In development [GID-TA10499] Expected publication date: TBC
-
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
In development [GID-TA10416] Expected publication date: TBC
-
OTL-200 for treating metachromatic leukodystrophy [ID1666]
In development [GID-HST10028] Expected publication date: 13 August 2021
-
Vaccine uptake in the general population
In development [GID-NG10139] Expected publication date: 06 April 2022
-
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
In development [GID-TA10597] Expected publication date: 27 October 2021
-
Looked-after children and young people
In development [GID-NG10121] Expected publication date: 27 September 2021
-
Cenobamate for focal onset seizures in epilepsy [ID1553]
In development [GID-TA10661] Expected publication date: 28 July 2021
-
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 10 May 2022
-
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
In development [GID-TA10244] Expected publication date: TBC
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488
In development [GID-TA10432] Expected publication date: TBC
-
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]
In development [GID-TA10470] Expected publication date: 27 January 2021
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
In development [GID-TA10472] Expected publication date: 02 June 2021
-
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]
In development [GID-TA10626] Expected publication date: 21 July 2021
-
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]
In development [GID-TA10703] Expected publication date: 21 July 2021
-
Givosiran for treating acute hepatic porphyria [ID1549]
In development [GID-HST10035] Expected publication date: 04 August 2021
-
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]
In development [GID-TA10493] Expected publication date: TBC
-
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]
In development [GID-TA10381] Expected publication date: TBC
-
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]
In development [GID-TA10406] Expected publication date: TBC
-
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]
In development [GID-TA10482] Expected publication date: 21 July 2021
-
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]
In development [GID-TA10513] Expected publication date: TBC
-
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]
In development [GID-TA10650] Expected publication date: 25 August 2021